Dexcom (DXCM) Accumulated Expenses (2010 - 2026)

Dexcom (DXCM) has reported Accumulated Expenses for 17 consecutive years, with $2.2 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Accumulated Expenses rose 12.74% year-over-year to $2.2 billion in Q2 2026; TTM through Jun 2026 was $2.2 billion, a 12.74% increase from a year earlier, with the FY2025 full-year figure at $1.9 billion, up 22.64% from the prior year.
• Accumulated Expenses was $2.2 billion for Q2 2026 at Dexcom, up from $2.1 billion in the prior quarter.
• Over five years, Accumulated Expenses peaked at $2.2 billion in Q2 2026 and troughed at $603.1 million in Q1 2022.
• A 5-year average of $1.4 billion and a median of $1.5 billion in 2024 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses jumped 79.68% in 2023 and climbed 12.74% in 2026, its largest moves.
• Over 5 years, Accumulated Expenses stood at $901.8 million in 2022, then soared by 49.2% to $1.3 billion in 2023, then climbed by 17.81% to $1.6 billion in 2024, then climbed by 22.64% to $1.9 billion in 2025, then climbed by 12.73% to $2.2 billion in 2026.
• The last three Accumulated Expenses figures came in at $2.2 billion (Q2 2026), $2.1 billion (Q1 2026), and $1.9 billion (Q4 2025), per Business Quant data.